Clostridium botulinum neurotoxin (BoNT) is the causative agent of botulism, a neuroparalytic disease. We describe here a semisynthetic strategy to identify inhibitors based on toosendanin, a traditional Chinese medicine reported to protect from BoNT intoxication. Using a single molecule assay of BoNT serotypes A and E light chain (LC) translocation through the heavy chain (HC) channel in neurons, we discovered that toosendanin and its tetrahydrofuran analog selectively arrest the LC translocation step of intoxication with subnanomolar potency, and increase the unoccluded HC channel propensity to open with micromolar efficacy. The inhibitory profile on LC translocation is accurately recapitulated in 2 different BoNT intoxication assays, namely the mouse protection and the primary rat spinal cord cell assays. Toosendanin has an unprecedented dual mode of action on the protein-conducting channel acting as a cargo-dependent inhibitor of translocation and as cargo-free channel activator. These results imply that the bimodal modulation by toosendanin depends on the dynamic interactions between channel and cargo, highlighting their tight interplay during the progression of LC transit across endosomes.
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natural product ͉ protein translocation ͉ small molecule modulator T he BoNTs comprise a family of 7 immunologically distinct proteins synthesized by strains of anaerobic bacteria. These toxins (BoNT/A-G) are the most lethal poisons known, with BoNT serotype A (BoNT/A) having a LD 50 for a 70-kg human of a mere 0.7-0.9 g by inhalation (1) . All BoNT serotypes are disulfide-linked di-chain proteins consisting of a 50-kDa light chain (LC) Zn 2ϩ -metalloprotease and a 100-kDa heavy chain (HC). The HC encompasses the translocation domain (TD) and the receptor-binding domain (RBD), conventionally denoted as H N and H C (2, 3) . The conspicuously specific activity of BoNT to selectively disable synaptic vesicle exocytosis has transformed this protein into the first bacterial toxin approved by the FDA for treatment of a number of diseases characterized by abnormal muscle contraction, a blockbuster cosmeceutical, and a highly feared bioweapon (1, 4, 5) . Functionally, these clostridial toxins inhibit the release of acetylcholine at neuromuscular junctions through a multistep mechanism that ultimately culminates in the cleavage of Soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor proteins, resulting in progressive flaccid paralysis (6) (7) (8) .
The major limonoid constituent of the bark of the tree M. toosendan, the triterpenoid toosendanin 1 (Fig. 1) , has been reported to possess activities ranging from ascarifuge to antibotulinum (9) (10) (11) (12) . Specifically, studies conducted over twenty years ago purported that toosendanin could protect monkeys from BoNT/A, BoNT/B, and BoNT/E-induced death in a dosedependent fashion when coadministered with, or several hours after, neurotoxin administration (9) (10) (11) (12) . These reports, although mechanistically unclear, were still intriguing in that toosendanin might provide the basis of an unmet challenge, a small molecule therapeutic for the treatment of botulinum intoxication. Given that a primary event for intoxication is the translocation of internalized toxin across intracellular membranes to reach its cytosolic targets (7, 8) , and that the structure of toosendanin would likely preclude it from inhibiting the BoNT/A LC metalloprotease (13) nor BoNT binding to cells (11) suggests that toosendanin could operate by hindering LC translocation out of the endosome. Herein, we report that the mechanism of action of toosendanin stems from its ability to alter LC translocation through the HC channel/chaperone; addition of toosendanin at the onset of LC translocation arrests this process, whereas exposure to toosendanin after completion of cargo translocation modulates HC channel activity, increasing the time the channel resides in the open state. These findings disclose an unprecedented bimodal action of a small molecule on a transmembrane chaperone: cargo-dependent inhibitor of translocation and cargo-free channel activator.
Results

Semisynthetic Analysis and Analog Preparation.
Based on first principles, it was not clear how to dissect the complex molecular architecture of toosendanin and elucidate the mechanistic nature of its antibotulinal properties. Hence, we turned to semisynthesis to generate a set of rationally designed toosendanin analogs. Examination of the molecular architecture of toosendanin reveals 3 key functionalities that could possibly contribute to the observed biological activity: (i) the hemiacetal bridge spanning C10 and C4 of the core ABCD fused ring system; (ii) the heterocyclic furan attached to C17; and (iii) the epoxide at C14 and C15 (Fig. 1) . Each of these moieties is rare in characterized steroidal structures, with the latter two being common only to the limonoid family of triterpenoids. Trapping of the hemiacetal was accomplished by treatment of the parent compound with N-methylmorpholine N-oxide (NMO) and catalytic amount of tetra-n-propylammonium perruthenate (TPAP) (14) to oxidize all alcohols, thus disallowing the open hemiacetal and generating lactone analog 2 (Fig. 1) . Heterocyclic furan functionalities are generally considered toxic to mammalian species (15) . To specifically remove the furan, toosendanin was treated with palladium on alumina and hydrogenated using standard conditions to give tetrahydrofuran analog 3 (THF-toosendanin) (Fig. 1) . Epoxide moieties are uncommon in natural products in light of the ensuing high reactivity, and in the case of toosendanin, this reactivity should be significantly enhanced due the unfavorable ring strain imparted by the [6, 5] CD fused ring system. However, this ring strain can also be exploited to drive a [1, 2] -rearrangement and the subsequent formation of a thermodynamically more stable ketone 4 ( Fig. 1) . In addition to probing these rare structural features, toosendanin also possesses other functional groups anticipated to have low in vivo stability. In particular, the acetate functionalities at C3 and C12 would be labile and could be rapidly hydrolyzed by serum esterases, including butyrylcholinesterase and liver carboxylesterases (16) . To mimic this reaction, the two acetates were excised without impinging upon the other functionalities under hydrolysis conditions optimized to selectively hydrolyze the desired esters without altering other base-labile sites to yield deacylated toosendanin analog 5 (Fig. 1) .
In Vivo Testing of Toosendanin Analogs. The previously reported antibotulinal activity of toosendanin was confirmed in a mouse lethality bioassay for BoNT/A intoxication. This model has been well-established as the FDA standard for assessing BoNT potency and is widely used in the study of BoNT antagonists (17) . Toosendanin extended the time to death (TTD) Ϸ4-fold from a single injection at the highest toosendanin dose (7.1 h in control animals versus Ͼ28 h TTD, using 2.5 mM toosendaninequivalent to 7.5 mg/kg) ( Fig. 2A and Table S1 ). Additionally, no toxicity of the compound alone was observed at this dose. Toosendanin analogs (2) (3) (4) (5) were tested in the mouse bioassay to ascertain the specific functional groups of the parent compound that are critical for prevention of BoNT-induced death. Of all tested synthetic compounds, only 3 had equivalent activity to toosendanin and could protect mice from death (Fig. 2 A) .
In Vitro Testing of Toosendanin. Confirmation of the in vivo activity of toosendanin and respective new analogs allowed investigations into the mechanistic nature of the antibotulinal action. First, the effects of toosendanin on the recombinant BoNT/A light chain was undertaken. LC/A catalytic activity was measured using a fluorescence resonance energy transfer assay (18); no effect was observed on the LC/A protease activity even at mM concentrations (Fig. S1 ).
Accordingly, we investigated the effect of toosendanin, using a sensitive and specific spinal cord cell-based assay validated for the activity of both BoNT serotypes A and E (19) . Exposure of neurons to BoNT/A in presence of increasing concentrations of toosendanin (TSDN) results in gradual preservation of intact, uncleaved SNAP-25 (synaptosomal-associated protein with M r ϭ 25 kDa), the intracellular BoNT/A and BoNT/E substrate, becoming practically complete above 200 nM ( Fig. 2 B and C) ; the Effective Dose to achieve 50% of the response (ED 50 ) for BoNT/A was 55 Ϯ 2.7 nM. Similar studies conducted with BoNT/E demonstrated nearly complete SNAP-25 protection at 1 M (Fig. S2 ) with the ED 50 value for BoNT/E ϭ 289 Ϯ 14.3 nM. To examine whether preservation of SNAP-25 by toosendanin involves a direct interaction with BoNT/A or BoNT/E before neuronal entry, 3 different protocols were performed in parallel. First, BoNT/A or BoNT/E and toosendanin were preincubated for 1 h before cell exposure; second, cells were exposed to BoNT/A or BoNT/E for 2 h before addition of toosendanin; and third, BoNT/A or BoNT/E and toosendanin were combined and immediately added to the cells. No significant difference in inhibition of BoNT/A-or BoNT/E-induced SNAP-25 cleavage between the different protocols was observed. The inhibition of BoNT/A-and BoNT/E-catalyzed cleavage of SNAP-25 in spinal cord neurons by toosendanin is consistent with a site of action at the passage of the LC from the interior of the endosome into the cytosol thereby preventing contact between the protease and its SNARE substrate. The higher potency of toosendanin against BoNT/A versus BoNT/E may arise from the construed slower translocation of the BoNT/A LC out from the endosome compared with BoNT/E (20, 21) . The toosendanin-evoked preservation of neuronal SNAP-25, an entity that is essential for synaptic vesicle fusion Table S1 ).
Single-Molecule Assay of Translocation Inhibition. A key step in intoxication is the translocation of BoNT LC by the BoNT HC channel (22) (23) (24) (25) . We developed an assay to investigate the dynamics of translocation focusing on the interactions between the HC channel/chaperone and its LC cargo for both BoNT/A and BoNT/E serotypes (23, 24) . Using this assay, the translocation process is monitored in real time and at the single-molecule level in excised membrane patches from Neuro 2A cells (23, 24) . Translocation requires pH 5.3 on the cis compartment, defined as the compartment containing BoNT, and pH 7.0 on the trans compartment, which is supplemented with the membrane nonpermeable reductant TCEP, conditions that emulate those prevalent across endosomes (23, 24) . Translocation is then observed as a time-dependent increase in Na ϩ conductance (␥) through the HC channel (23, 24) , as illustrated for BoNT/A by the control experiment shown in Fig. 3A . The time course of ␥ change after insertion of BoNT/A holotoxin into the membrane displays multiple transient intermediate conductances before achieving a ␥ of 67.1 Ϯ 2.0 pS (Fig. 3A Right) (24) . This steady-state ␥ is also a hallmark of isolated HC recorded under identical conditions (22) ; therefore it represents the conductance of the cargo-free, protein-conducting channel generated after LC translocation is complete (22) (23) (24) . We infer that these conductance intermediates, observed as occluded states, correspond to permissible chaperone-cargo conformations populated during protease translocation; concomitantly, the proteinconducting channel progressively conducts more Na ϩ around the polypeptide chain before entering an exclusively ion-conductive state (22) (23) (24) . Transformation of an occluded state characterized by low ␥ intermediates into an unoccluded channel with ␥ ϳ 65 pS only occurs after the LC completes translocation.
Toosendanin Is a Cargo-Dependent Inhibitor of the BoNT ProteinConducting Channel. Toosendanin arrests LC translocation, as shown in Fig. 3B . BoNT/A holotoxin channels were allowed to form in the absence of toosendanin; after onset of low conductance channel activity, toosendanin was added to the trans compartment. Although 0.4 nM toosendanin has no effect on LC translocation, 4 nM toosendanin persistently arrests channel activity at an intermediate step of LC translocation (23, 24) . Exposure to higher toosendanin concentrations at this early step in translocation progressively inhibits it more effectively and, at 40 M toosendanin, irreversibly blocks translocation (Fig. 3B  bottommost image) (23, 24) .
In sharp contrast, addition of toosendanin after LC translocation has completed unexpectedly results in altered channel kinetics rather than channel blockade. Although ␥ of the unoccluded HC channel (␥ ϳ 66 pS) remains constant, the probability of the channel residing in the open state (P o ) increases (22) . As low as 0.4 M toosendanin augments the P o , promoting a prolonged residence in the open state, in a dose-dependent manner (Fig. 3C) .
Analysis of the channel kinetics for BoNT/A exposed to toosendanin before and after completion of LC translocation resolves a unique interaction pattern between toosendanin and the HC channel. The time course of productive LC translocation exhibits an average half-time for completion (t), estimated from the transition to high conductance, of 150 Ϯ 25 s (Fig. S3) . At 0.4 nM, toosendanin delays the completion of LC translocation (t ϭ 220 Ϯ 10 s, Fig. S3 ). Addition of 4 nM toosendanin allows progression with a t of ϳ350 s to an intermediate occluded state characterized by an average ␥ ϳ 35 pS (Fig. 4A and Fig. S3 ). Above 4 nM, toosendanin aborts translocation blocking the BoNT/A channel in a low conductance, occluded state (22) (23) (24) (25) . Toosendanin, therefore, arrests LC/A translocation by the BoNT/A protein-conducting channel with an ED 50 value of 4.0 Ϯ 1.8 nM (Fig. 4A) . absence of toosendanin and shifts to approximately ϩ63.7 Ϯ 5.4 mV in its presence ( Fig. 4B and Fig. S3 ). Channel activity is drastically modified from being evoked exclusively at negative potentials in absence of toosendanin to being elicited at progressively more positive potentials with increasing toosendanin concentration. At 40 M toosendanin, transitions to the open state persist at and above ϩ100 mV ( Fig. 4B and Fig. S3 ).
Modulation by toosendanin of unoccluded BoNT/A channel activity, quantified from measurements of the V 1/2 , show an ED 50 ϭ 8.9 Ϯ 1.8 M, a concentration Ϸ2,000-fold above that necessary to arrest LC translocation (Fig. 4B) . Thus, toosendanin effectively acts as an activator of the cargo-free proteinconducting HC/A channel generated after productive cargo translocation.
Toosendanin Modulates Both Cargo-Dependent and Cargo-Free Activities of the BoNT/E Protein-Conducting Channel. Toosendanin arrests translocation of BoNT/E LC at 400 nM (Fig. 5A ) as effectively as BoNT/A LC at 40 nM (Fig. 3B) . At 4 nM toosendanin, the BoNT/E protein-conducting channel remains occluded at an intermediate translocation step characterized with a ␥ ϳ 50 pS ( Fig. 5 A and B) . At 400 nM, toosendanin aborts translocation at an occluded state characterized by an average ␥ ϳ 24 pS (Fig. 5B ). Similar to its activity on the unoccluded HC/A channel (Fig.  4B) , toosendanin increases the HC/E channel P o and shifts the voltage dependence of the channel residing in the open state toward more positive potentials (Fig. 5C) . At 40 M, toosendanin shifts the BoNT/E HC channel V 1/2 from approximately Ϫ45 mV to approximately ϩ65 mV, whereas at 4 nM toosendanin shifts the V 1/2 to Ϸ10 mV (Fig. 5D) . Thus, the BoNT/E HC channel activity evoked at negative potentials is sensitive to toosendanin at nM concentrations, a pattern comparable to that recorded for the BoNT/A HC channel (Figs. 4B an Fig. S3 ).
Of note is the fact that in the highly sensitive spinal cord cell assay, the minimum dose of toosendanin needed to detect significant preservation of intact SNAP-25 was 8 nM for BoNT/A (Fig. 2 B and C) and 40 nM for BoNT/E (Fig. S2) . These values are in fair agreement with the results obtained for BoNT/A and BoNT/E on the single molecule translocation assay (Figs. 3-5 ).
Toosendanin Analogs Active in Vivo Recapitulate the Mechanism of the Parent Compound. For BoNT/A, the mouse toxicity bioassay predicted THF-toosendanin (analog 3) to be as active as toosendanin. As detected by the single molecule assay, 4 nM THF-toosendanin blocks translocation of BoNT/A LC as effectively as toosendanin. However, even at 0.4 nM, a concentration at which toosendanin is inactive, the THFtoosendanin delays cargo translocation by an average of 17 min (Fig. 6A) . The protein-conducting channel remains occluded at an intermediate translocation step characterized with a ␥ ϳ 30 pS (Fig. 6B) . In contrast, 4 nM toosendanin is required to achieve this effect (Fig. 4 A) . At 40 nM, THF-toosendanin aborts translocation at an occluded state with a ␥ ϳ 10 pS (Fig.  6B) . Thus, THF-toosendanin is an Ϸ10-fold more potent inhibitor of LC/A translocation than toosendanin. Similarly, 40 nM THF-toosendanin has an effect equivalent to that of 40 M toosendanin on the unoccluded HC/A channel (Fig. 6C ). It appears, therefore, to be Ϸ1,000-fold more potent activator of the cargo-free HC/A channel than toosendanin. THFtoosendanin modifies the channel gating kinetics in a concentration-dependent manner shifting the V 1/2 to more positive voltages and increasing P o (Fig. 6D) . These features are similar to those produced by toosendanin on the HC/A channel (Fig. 4 C  and D) . The deacetylated toosendanin, as a positive control, displayed neither cargo-dependent nor cargo-free activity on the BoNT/A protein-conducting channel (data not shown).
Discussion
An urgent goal is to identify selective and protective agents directed to prevent or relieve the neuroparalytic toxic actions of BoNTs. Our results suggest that toosendanin is a multiserotype antibotulinal agent. The basis of the protection from BoNT intoxication engendered by toosendanin is not apparent from simple analysis of its complex molecular architecture (Fig. 1) . Our approach centered upon the systematic elimination of functional groups that are unique to toosendanin and the limonoid class of steroids, and those moieties that are metabolically labile and easily removed in vivo. Of this set of molecules, only the reduction of the furan heterocycle to the corresponding tetrahydrofuran analog led to a retention of biological activity as measured by extension of the TTD in a murine bioassay (Fig.  2 A) , despite the presence of a diastereomeric pair of compounds. This finding is particularly intriguing given that other functional groups including the C3 and C12 acetates and the C14-C15 epoxide would be anticipated to be very labile in vivo, yet their presence is indispensable for the emergence of BoNT protection.
Toosendanin arrests translocation by stabilizing nonpermissive conformations of the HC channel-LC complex during the early steps of LC translocation (Figs. 3 A and B and 4A for BoNT/A and Fig. 5 for BoNT/E). In contrast, binding of toosendanin to the unoccluded HC channel modulates the gating kinetics leading to a preponderantly open channel entity (Figs.  3C, 4B , and 5C and D), implying that it would facilitate the catastrophic dissipation of the electrochemical gradients across endosomes. This dual modality, the transformation of toosendanin from an inhibitor of cargo translocation to an activator of the protein-conducting channel, is determined by the presence, and by inference, by the conformation of cargo within the chaperone. Toosendanin may inhibit cargo translocation by stabilizing cargochaperone conformers that, given the transient nature of the transit process, are short-lived. In contrast, the cargo-free channel must necessarily expose a different binding site to toosendanin, which ultimately stabilizes an open conformation.
The single molecule translocation assay dictates that the signal arising from the inserted channel occluded by the cargo must be detected before exposure to toosendanin. This protocol insures that channel formation and insertion has occurred and that the intermediate conductances, reporters of the translocation process, are monitored precisely at the onset of translocation (22) (23) (24) . The fact that toosendanin acts on the unoccluded HC channel of both BoNT/A and BoNT/E and modulates the residence time of the channel in the open state indicates that the interaction of toosendanin is directly on the membraneembedded HC channel. Taken together, we favor the interpretation that toosendanin acts on the regions of the HC channel confined within the lipid bilayer both when occluded by the LC cargo or unoccluded after completion of cargo translocation, this notion being valid for both BoNT/A and BoNT/E serotypes.
The BoNT channel is closed under conditions akin to those prevalent across endosomes (22) (23) (24) . After LC translocation, the closed HC channel conformation precludes the passive dissipation of the electrochemical gradients across endosomes. Micromolar concentrations of toosendanin shift the voltage dependence of the unoccluded HC channel (Figs. 4B and 5D ), effecting a higher propensity to reside in the open state. Accordingly, dissipation of electrochemical gradients would ensue and disrupt endosomal function, potentially harming critical host cellular processes. Interestingly, the modulation of HC channel activity by toosendanin occurs at a concentration Ϸ2,000-fold higher than that at which LC translocation is efficiently arrested. This bimodal modulation of BoNT channel activity is sufficiently disparate in concentration as to promote toosendanin use as a prophylactic agent.
The HC channel represents a realistic target for inhibition of BoNT neurotoxicity. Blocking the BoNT protein-conducting channel with small molecules would abort translocation of the protease, thereby abrogating its toxicity. The goal is to identify a single class of compounds that would be effective against all BoNT serotypes irrespective of receptor binding, specific protease substrate or antigenic properties. The crystal structures of the 7 LC serotypes have been solved, some with small molecules coordinated in the active site (2, 3, (26) (27) (28) (29) (30) (31) , making small molecule interaction modeling a powerful tool (6) . Unfortunately, these compounds display broad cross-reactivity as the active site is highly conserved across cellular proteases and not involved in specific substrate recognition. For BoNT/A, the extended enzyme substrate interface required for optimal substrate recognition involves an array of substrate binding sites distant from the active site (29, 32) . These exosites may be a more effective target to attenuate the protease;, however, specific serotypes have different substrates, requiring design of 7 unique inhibitors.
Studies focused on early stages of intoxication aim to develop blockers of the interaction between the BoNT RBD (H C ) with known receptors (33) . This strategy, still in development, is limited to those serotypes for which the protein coreceptor has been identified: SV2 for BoNT/A (34, 35) and BoNT/E (36) and synaptotagmin II for BoNT/B (37, 38) and G (39). The RBD (H C ) and LC serotype specificity is attributed to interactions with host cellular proteins; in contrast, the TD (H N ) functions to chaperone the LC cargo. The TD may function as a universal protein translocator; small molecules that inhibit BoNT/A channel activity (Figs. 3, 4 , and 6) exhibit similar effects on BoNT/E (Fig. 5 ) thereby eliminating the necessity to develop multiple entities.
In light of these previous studies, our work highlights the BoNT channel as a viable therapeutic target for intervention using small molecules. We envision toosendanin and/or THFtoosendanin to be developed into natural product-derived lead compounds with both a prophylactic and therapeutic potential as selective antibotulinal agents that could be deployed to military personnel and civilian populations at high risk.
Materials and Methods
Synthetic procedures for toosendanin analogs and protease activity of BoNT/A light chain are presented in SI Text.
Materials.
Unless otherwise specified, all chemicals were purchased from Sigma-Aldrich. Purified native BoNT/A and BoNT/E holotoxins were prepared from C. botulinum strains Hall A hyper (40) and Beluga E (41) as previously described and were purchased from Metabiologics or prepared in E.A.J.'s laboratory. Toosendanin was purchased from Apin Chemicals.
In Vivo Assay. Female CD-1 outbred mice (17-23 g; Harlan Sprague-Dawley) were injected intravenously into the left-hand lateral tail vein with test compounds and, immediately after with BoNT essentially as described (17, 18) . Animals were observed for signs of botulism overnight, and the time of death in minutes was recorded.
Primary Rat Spinal Cord Cells Assays. Primary rat spinal cord cells were prepared and maintained as described in ref. 19 . Toosendanin and 250 pg of BoNT/A or BoNT/E (Ϸ20 mouse LD 50 Units, and 5.6 pM), toosendanin alone, or BoNTs alone were mixed and immediately added to cells, followed by incubation at 37°C for 22 h. The cells were lysed and samples were analyzed by Western blot and densitometry (19) . See SI Text for details.
Cell Culture and Patch Clamp Recordings. Excised patches from neuroblastoma Neuro 2A cells in the inside-out configuration were used as described (22) (23) (24) . Current recordings were obtained under voltage clamp conditions. Records were acquired at a sampling frequency of 20 kHz and filtered online to 2 kHz with Gaussian filter. All experiments were conducted at 22 Ϯ 2°C. Analysis was performed on single bursts of each experimental record. Only single bursts were analyzed because of the random duration of quiescent periods. See SI Text for details.
